Pharnext to Attend November Investors Conferences
November 02 2017 - 11:45AM
Business Wire
Regulatory News:
Pharnext SA (FR0011191287 - ALPHA)(Paris:ALPHA), a
biopharmaceutical company pioneering a new approach to the
development of innovative drugs based on the combination and
repositioning of known drugs, today announced that senior
management will be attending the following conferences taking place
in November 2017 throughout Europe.
- BIO-Europe® 20171, on November
6-8, 2017 at CityCube Berlin, Berlin, Germany.
- Jefferies 2017 London Healthcare
Conference2 on November 16, 2017 in London, United
Kingdom.
- Actionaria3,
Individuals shareholders exhibition on November
23-24, 2017 at Palais des Congrès, Paris, France.
- Corporate Overview Presentation:
during "Facing the leaders" on November 23, from 3:45pm to 4:00pm
CET. Speaker : Mr. Olivier Legrand, Pharnext.
- Geneva European Midcap Event4 on
November 28, 2017 in Geneva, Switzerland.
If you are interested in meeting the Pharnext management team
during either of these events or if you need more information about
Pharnext's participation, please send an email to
investors@pharnext.com.
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company
founded by renowned scientists and entrepreneurs including
Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has
two lead products in clinical development. PXT3003 is currently in
an international Phase 3 trial for the treatment of
Charcot-Marie-Tooth disease type 1A and benefits from orphan drug
status in Europe and the United States. PXT864 has generated
positive Phase 2 results in Alzheimer’s disease. Pharnext is the
pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company
identifies and develops synergic combinations of repositioned drugs
at new optimal lower doses. These PLEODRUG™ offer several key
advantages: efficacy, safety and intellectual property including
several product or composition of matter patents already granted.
The Company is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris
(ISIN code: FR0011191287).For more information, visit
www.pharnext.com.
1 https://ebdgroup.knect365.com/bioeurope/about-bio-europe2
http://www.jefferies.com/OurFirm/Conferences/325/3523
http://www.actionaria.com/4
http://www.midcapevents.com/geneva2017/home/
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171102005049/en/
PharnextXavier Paoli, +33 (0)1-4109-2230VP, Chief
Commercial Officercontact@pharnext.comorInvestor Relations
(Europe)MC Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorInvestor Relations
(U.S.)Stern Investor Relations, Inc.Matthew Shinseki,
+1-212-362-1200matthew@sternir.comorFinancial Communication
(France)ActifinStéphane Ruiz, +33
(0)1-5688-1115sruiz@actifin.frorMedia Relations
(Europe)ALIZE RPCaroline CarmagnolAurore
Gangloffpharnext@alizerp.com+33 (0)1-4454-3664orMedia Relations
(U.S.)RooneyPartnersMarion Janic,
+1-212-223-4017mjanic@rooneyco.com
Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024